Core Viewpoint - Enwei Pharmaceutical, established in 2005 and listed in 2022, specializes in the pharmaceutical sector with a focus on gynecology, pediatrics, and respiratory medications, holding a notable brand presence in China [1] Financial Performance - For Q3 2025, Enwei Pharmaceutical reported revenue of 637 million yuan, ranking 51st among 69 companies in the industry, with the industry leader, Baiyunshan, generating 61.606 billion yuan [2] - The company's net profit for the same period was 36.5847 million yuan, placing it 46th in the industry, while the top performer, Yunnan Baiyao, reported a net profit of 4.789 billion yuan [2] Financial Ratios - As of Q3 2025, Enwei Pharmaceutical's debt-to-asset ratio was 27.60%, lower than the industry average of 32.81% [3] - The company's gross profit margin stood at 48.22%, which is below the industry average of 52.44% [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 13.72% to 6,340, while the average number of shares held per shareholder increased by 261.71% to 16,200 [5]

Core Viewpoint - Enwei Pharmaceutical reported a revenue of 188 million yuan for Q3 2025, representing an increase of 8.97% year-on-year, but incurred a net loss of 1.76 million yuan due to production line upgrades and increased marketing expenses [1] Group 1 - The company achieved a revenue of 188 million yuan in Q3 2025, which is an 8.97% increase compared to the same period last year [1] - The net profit for the quarter was a loss of 1.76 million yuan, primarily due to the impact of technical upgrades on the core product production line and rapid expansion of the e-commerce division [1] - The production line upgrade for the core product, Jieryin Wash, affected the shipment progress of certain product specifications, but the construction was nearly completed by the end of Q3, allowing for recovery in production and shipping [1]

Core Viewpoint - The company has announced the achievement of conditions for the second phase of its restricted stock incentive plan, allowing 106 eligible participants to claim a total of 799,271 shares at an adjusted price of 13.48 yuan per share, which represents 0.7768% of the company's total share capital [10][40]. Financial Data - The company confirmed that the third-quarter financial report was not audited [7]. - The financial report includes no adjustments or restatements of previous years' accounting data [3]. - The company reported no non-recurring gains or losses applicable [3]. Shareholder Information - The total number of shareholders holding more than 5% of shares and the top ten shareholders' holdings were not applicable for this report [5]. - The company has not experienced any changes in the lending of shares by major shareholders due to margin trading [5]. Incentive Plan Details - The second phase of the restricted stock incentive plan involves 106 eligible participants and a total of 799,271 shares [9][10]. - The adjusted grant price for the second phase is set at 13.48 yuan per share [11]. - The source of the shares for this incentive plan is from the company's repurchase of A-share common stock from the secondary market [12]. Approval Process - The board of directors approved the achievement of the second phase conditions on October 29, 2025, with unanimous support [36]. - The incentive plan has undergone necessary approvals and has been publicly disclosed as required [47][50]. Performance Conditions - The performance assessment for the incentive plan is based on company-level metrics for the fiscal years 2023-2025, with specific targets set for each year [22]. - Individual performance assessments will also be conducted according to the company's existing compensation and evaluation regulations [22]. Impact on Financial Status - The company anticipates that the stock grants will not significantly impact its financial status or operational results, as the total share capital will remain unchanged [49]. - The company will adjust the accounting treatment of the stock grants according to the applicable accounting standards [49].

Core Viewpoint - The company has adjusted the grant price and quantity of the second category of restricted stock in its 2023 incentive plan, which will not significantly impact its financial status or operational results [4][15][27]. Summary by Sections Incentive Plan Adjustments - The company held its third board meeting on October 29, 2025, where it approved the adjustment of the grant price for the second category of restricted stock to 13.48 yuan per share and agreed to void 21.8821 thousand shares that were granted but not vested [9][25]. - The adjustment was made following the completion of the 2024 annual profit distribution, which involved a cash dividend of 1.80 yuan per 10 shares, totaling approximately 18.19 million yuan [10][15]. Approval Process - The company followed necessary approval procedures for the 2023 restricted stock incentive plan, including meetings of the board and supervisory committee, and received independent opinions from legal and financial advisors [2][4][21]. - The plan was publicly disclosed, and no objections were raised during the internal announcement period [6][22]. Impact of Adjustments - The adjustments to the grant price and the voiding of certain shares will not materially affect the company's financial condition or management stability, and the management team will continue to fulfill its responsibilities [15][27]. - The voided shares accounted for approximately 0.2127% of the company's total share capital [26]. Legal Opinions - Legal opinions confirm that the adjustments and the conditions for vesting have been met in accordance with relevant regulations, ensuring compliance with the management and incentive plan guidelines [17][29].

证券代码：301331 证券简称：恩威医药 公告编号：2025-046 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 恩威医药股份有限公司（以下简称"公司"）第三届董事会第八次会议于 2025 年 10 月 29 日以现场及通讯方式召开。本次会议通知于 2025 年 10 月 20 日以通 讯方式发出，本次会议应参会董事 8 名，实际参会董事 8 名，黎春独立董事以 通讯方式参加会议。会议由董事长薛永江主持召开。本次会议的召开符合《公 司法》和《公司章程》的有关规定，所做决议合法有效。 二、董事会会议审议情况 1、审议通过了《关于<公司 2025 年第三季度报告>的议案》 经审核，董事会认为：公司 2025 年第三季度报告包含的信息公允、全面、 真实的反映了本报告期的财务状况和经营成果等事项，所披露的信息真实、准 确、完整，不存在任何虚假记载、误导性陈述或重大遗漏。 恩威医药股份有限公司 第三届董事会第八次会议决议公告 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）上的相关 公告。 表决结果：8 票同意，0 ...

Financial Performance - The company's revenue for Q3 2025 was ¥187,632,107.25, representing an increase of 8.97% year-over-year[5]. - Total operating revenue for the period reached ¥636,853,560, an increase of 13.6% compared to ¥560,341,100.40 in the previous period[20]. - Net profit for the period was ¥36,584,661.67, representing a significant increase of 66.5% from ¥22,021,962.58 in the prior period[21]. - Basic earnings per share increased to ¥0.3668, compared to ¥0.2183 in the previous period, marking a growth of 67.9%[22]. Profitability and Losses - The net profit attributable to shareholders was a loss of ¥1,759,519.58, a decrease of 143.05% compared to the same period last year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥3,403,801.61, down 164.61% year-over-year[5]. - The company reported a weighted average return on equity of -0.16% for the current period, down 0.53% year-over-year[5]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,496,708,751.53, a decrease of 0.52% from the end of the previous year[5]. - Total liabilities decreased to ¥413,060,476.78 from ¥446,857,834.56, a reduction of 7.6%[19]. - The total non-current assets included investment properties valued at ¥26,678,462.45, down from ¥28,476,170.60, a decrease of about 6.3%[17]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 6,340, with the largest shareholder holding 28.90% of the shares[11]. - The total number of shares held by the top 10 shareholders amounted to 69,790,184 shares, with significant holdings from Chengdu Enwei Investment Group Co., Ltd. at 29,733,200 shares[15]. - The company’s major shareholders are identified as acting in concert, controlling approximately 69.01% of the shares collectively[15]. Cash Flow and Investments - The cash flow from operating activities for the year-to-date was ¥76,202,035.01, an increase of 6.63% compared to the previous year[5]. - Total cash inflow from investment activities was $1,267,294,447.06, significantly higher than $640,603,505.93, marking an increase of approximately 97.8%[24]. - Net cash flow from investment activities was -$79,417,346.60, worsening from -$13,484,580.01 in the prior period[24]. Operational Metrics - Total operating costs amounted to ¥603,849,773.06, up from ¥534,869,746.20, reflecting a rise of 12.9%[20]. - The company experienced a 41.88% increase in trading financial assets, totaling ¥205,329,905.69, due to increased investment in financial products[10]. - The company reported a significant increase in investment income of 72.51%, amounting to ¥4,140,865.67, attributed to higher returns from financial products[10]. Strategic Focus - The company is focusing on expanding its market presence and investing in new product development to drive future growth[20]. - Research and development expenses were reported at ¥4,302,882.29, down from ¥5,770,697.03, indicating a strategic shift in resource allocation[20]. Cash Management - Cash and cash equivalents decreased to ¥319,607,373.19 from ¥370,274,493.59, reflecting a decline of about 13.7%[17]. - The ending balance of cash and cash equivalents stood at $259,566,279.03, down from $365,428,864.02[24]. - The net increase in cash and cash equivalents was -$29,657,510.52, contrasting with a positive increase of $129,612,081.81 in the previous period[24]. Accounting and Auditing - The company did not undergo an audit for the third quarter financial report[25]. - The company plans to implement new accounting standards starting in 2025[26].

证券代码：301331 证券简称：恩威医药 公告编号：2025-049 恩威医药股份有限公司 关于 2023 年限制性股票激励计划第二期归属条件成就的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、本次符合归属条件的激励对象人数：106 人。 2、本次第二类限制性股票拟归属数量为 79.9271 万股，占目前公司股本总 额的 0.7768%。 3、第二类限制性股票授予价格：13.48 元/股（调整后）。 4、归属股票来源：公司从二级市场回购的 A 股普通股股票。 5、本次归属的限制性股票待相关手续办理完成后，公司将发布相关上市流 通的公告，敬请投资者关注。 恩威医药股份有限公司（以下简称"公司"、"本公司"或"恩威医药"）于 2025 年 10 月 29 日召开第三届董事会第八次会议，审议通过了《关于 2023 年限制性 股票激励计划第二期归属条件成就的议案》，本次符合归属条件的激励对象共计 106 人，可申请归属的第二类限制性股票数量为 79.9271 股，占公司股本总额的 0.7768%，归属价格为 13.48 元/股（调整后）。 ...

关于作废部分已授予但尚未归属的第二类限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 恩威医药股份有限公司（以下简称"公司"、"本公司"或"恩威医药"）于 2025 年 10 月 29 日召开第三届董事会第八次会议，审议通过了《关于作废部分已授予 但尚未归属的第二类限制性股票的议案》。现将有关事项说明如下： 证券代码：301331 证券简称：恩威医药 公告编号：2025-050 恩威医药股份有限公司 一、公司 2023 年限制性股票激励计划已履行的相关审批程序 （一）2023 年 9 月 26 日，公司召开第二届董事会第十五次会议，审议通过 了《关于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于 公司<2023 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东 大会授权董事会办理股权激励相关事宜的议案》等议案，公司独立董事就本激励 计划发表了独立意见，律师、独立财务顾问出具了相应的意见与报告。 同日，公司召开第二届监事会第十四次会议，审议通过了《关于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》 ...

证券代码：301331 证券简称：恩威医药 公告编号：2025-048 恩威医药股份有限公司 关于调整 2023 年限制性股票激励计划第二类限制性股票 授予价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 恩威医药股份有限公司（以下简称"公司"、"本公司"或"恩威医药"）于 2025 年 10 月 29 日召开第三届董事会第八次会议，审议通过了《关于调整 2023 年限 制性股票激励计划第二类限制性股票授予价格的议案》。现将有关事项说明如下： 一、公司 2023 年限制性股票激励计划已履行的相关审批程序 （一）2023 年 9 月 26 日，公司召开第二届董事会第十五次会议，审议通过 了《关于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于 公司<2023 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东 大会授权董事会办理股权激励相关事宜的议案》等议案，公司独立董事就本激励 计划发表了独立意见，律师、独立财务顾问出具了相应的意见与报告。 同日，公司召开第二届监事会第十四次会议，审议通过了《关于公司<2023 年限制性 ...

上述事项符合相关法律、法规及规范性文件所规定的条件，不存在损害公司及 股东利益的情形。 恩威医药股份有限公司 董事会提名与薪酬委员会 恩威医药股份有限公司 提名与薪酬委员会关于 2023 年限制性股票激励计划第二期 可归属激励对象名单的核查意见 恩威医药股份有限公司（以下简称"公司"）提名与薪酬委员会根据《中华人民 共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简 称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办法》"）、 《深圳证券交易所创业板股票上市规则》（以下简称"《上市规则》"）、《深圳证 券交易所创业板上市公司自律监管指南第 1 号——业务办理》等有关法律、法规和 规范性文件以及《2023 年限制性股票激励计划（草案）》（以下简称"本激励计划"）、 《恩威医药股份有限公司章程》（以下简称"《公司章程》"）的规定，对本激励计 划第二期可归属的激励对象名单进行审核，发表核查意见如下： 本次拟归属的 106 名获授第二类限制性股票的激励对象符合《公司法》《证券 法》等法律、法规和规范性文件以及《公司章程》规定的任职资格，符合《管理办 法》《上市规则》等法律、法 ...